MacroGenics Gets Nod For Margenza In HER2-Positive Breast Cancer
Company Reaches Milestone With First FDA Approval
Executive Summary
The drug may see a muted launch given the competitive landscape and a broad label despite its efficacy advantage in F-allele patients.
You may also be interested in...
Finance Watch: Biopharma IPO Market Silence Continues In The US
Public Company Edition: The last biopharma IPO in the US was on 17 February and none have been scheduled, so far, for March. Also, another SPAC merger is called off, Travere sells $275m worth of notes and Xeris secures $150m in new debt, while Ovid, Passage Bio and others are cutting jobs.
Lackluster Survival Data Likely To Marginalize MacroGenics’ Margenza
While the general lack of an overall survival benefit for MacroGenics’ drug in later-line breast cancer was not surprising, OS data were seen as important for commercial uptake of the drug.
Byondis Seeks Partner For Lead ADC To Enter Crowded Breast Cancer Market
Top-line results from the Phase III TULIP study show that Byondis’s next-generation antibody-drug conjugate, trastuzumab duocarmazine (SYD985) is superior to physicians' choice of therapy for delaying disease progression in patients with advanced HER2-positive breast cancer.